Japan Finally Approves Mifepristone To Public Support
Use, Monitoring Requirements
Executive Summary
Japan has approved abortion drug mifepristone but will limit its use to clinics with authorized physicians, with strict nationwide monitoring of sales. The majority of more than 10,000 public comments around the approval were in support of the new option for women.
You may also be interested in...
Japan Review/Outlook: Pricing Tweaks Considered After Year Of Change
After a year of revising and opening up its regulations for new drugs in 2023, Japan is aiming to add more reimbursement pricing premiums for innovative medicines in 2024, while cautiously discussing other detailed revisions to regulations and the pricing system.
Supreme Court Declines ‘Skinny Label’ Case, But Teva To Continue Fight In District Court
Justice Kavanaugh voted to grant Teva’s petition for certiorari. It is unknown if other justices voted with him. The high court last month declined to hear Novartis's Gilenya patent case and Sanofi’s antitrust allegations against Mylan’s EpiPen rebate agreements.
Generic And Branded Mifepristone Remain On US Market Following Supreme Court Stay
GenBioPro will be able to continue selling its generic mifepristone, after the Supreme Court overruled a stay from the Fifth Circuit which could have seen generic approval rescinded and significant restrictions placed on the drug’s use.